Cryptoassets for income?

At our Quarterly Investment Forum, we discussed the signals that affirm our optimistic view on the economic outlook. Our experts also debated key issues with one discussion around the opportunities and challenges in crypo assets.

15 Mar 2021

At this Quarterly Investment Forum, we discussed the signals that affirm our optimistic view on the economic outlook and procyclical asset allocation. Our experts also discussed and debated key issues on the investment landscape: active versus passive management in emerging market equities, the opportunities and challenges in crypto, and the boom in special purpose acquisition companies (SPACs).

1Q 2021 Quarterly Investment Forum highlights

Macroeconomic and market outlook: Room to run

Nicole Goldberger, Portfolio Manager and Head of Growth Multi-Asset Portfolios

Growth is broadening. Powerful fiscal and monetary support coupled with an acceleration in vaccinations is bolstering our conviction in a synchronized global upswing. The passage of additional US fiscal stimulus fortifies our positive view on consumer spending. Income support programs introduced stateside have propelled incomes higher during the COVID-19-induced recession, which is in stark contrast to the environment that prevailed following the Global Financial Crisis. The share of countries in which manufacturing activity is expanding at an increasing rate is near levels reached in 2017. Such strong performance was able to be sustained for a considerable period. We expect a similar narrative to play out this time, with services sector activity also firming meaningfully as economic reopening allows for pent-up demand to be unleashed.

While 2020 was more about beta, we believe this year will be more about alpha in equities, and see greater room to run in relative value procyclical trades. In particular, we favor value relative to growth. Superior expected earnings growth may be an effective catalyst for value outperformance, as the cohort trades at depressed valuations to growth not seen since the dot-com bubble.

We prefer equities to credit, and credit relative to sovereign bonds, expecting further weakness in global duration. Some of our other favored assets include emerging market currencies and Asian credit that trade at inexpensive valuations and benefit from the continued improvement in global activity, as well as the carry available in US high yield compared to Treasuries.

Even after their recent rise, real yields remain at historically depressed levels, and offer support for risky assets. History suggests that equities are able to digest rising rates so long as credit spreads remain resilient. However, when real rates are rising very quickly, this can temporarily challenge the stock market. The recent experience shows that this abrupt rise in yields has been very positive for the value over growth positions in equities. Our optimistic view on risk assets could be challenged on a more protracted basis in the event that China’s credit impulse sharply contracts, or in the event that there is a regime shift to a persistently higher inflation backdrop.

EM: Active or passive?

Benita Mikolajewicz, Senior Equity Investment Analyst, and Boriana Iordanova, Index Research Analyst

The anticipated global economic upswing has increased the appeal of allocating to emerging markets, but the question lingers over whether to use active or passive vehicles to do so. The primary benefit of utilizing an active investment approach is that stocks are not covered as thoroughly by the analyst community as in developed markets. In addition, a substantial share of companies that have tripled in value over the past five years in Asia have limited coverage. This market inefficiency provides opportunities for active managers that engage in deep fundamental analysis. Some difficulties of the active approach in EM is that there are more illiquid stocks, and some vehicles may reach capacity constraints.

In utilizing passive vehicles to enhance emerging market exposure, these liquidity and capacity challenges can be largely overcome, and fees are lower. In addition, innovation in indexing over the past decade allows for a much higher degree of customization than was previously enjoyed. This can help drive excess returns and allow client preferences to continue to shape investment decisions.

Opportunities and limitations in crypto

Stefan Sabo, Multi-Asset Strategist and Michael Bolliger, Chief Investment Officer, Global Emerging Markets at UBS Wealth Management

The important technological development tied to cryptoassets and the blockchain is the ability to store and transfer value without a central counterparty, creating a system resilient to a whole host of shocks, and even censorship up to the nation-state level. The blockchain trilemma involves balancing the trade-offs between security, decentralization, and scalability, and there is currently no one perfect solution that balances all three of these pillars. While Bitcoin commands the most attention in the crypto space, Ethereum is actively focused on upgrading the speed and usefulness of its underlying infrastructure, with many potential benefits including better energy efficiency. Going forward, there are opportunities to bring parts of the conventional financial system onto the blockchain. In addition, some of these cryptoassets like Ethereum may be valued for their income-generating prospects.

These opportunities in crypto, however, must be weighed in relation to the volatility of the assets, high uncertainty surrounding end usage, and potential for enhanced regulatory scrutiny. Bitcoin has not yet proven its worth as a safe haven. Adding it to a portfolio in small amounts has increased the Sharpe ratio, but on a going forward basis it is a bold proposition to assume the magnitude of the price increases will persist or volatility will subside if the business case for this cryptoasset remains muddled.

The rich opportunity set in SPACs

Todd Godfrey and Blake Hiltabrand, UBS O’Connor

There has been a significant maturation of the special purpose acquisition company market in recent years along with an evolving investor base. SPACs have become a more attractive method of going public because of the certainty of execution, certainty of price, speed to market, and ability to discuss forward projections that aid in price discovery.

Exposure to SPACs offers optionality in two forms: the share itself is an option on the sponsor’s ability to create/unlock value, and the warrants attached to the share also retain some value. Sophisticated investors have opportunities to invest in SPACs in many different ways that have varying risk and return profiles, including pre-IPO financing, partnering with sponsors to provide “at risk” capital, and funding through PIPEs.

What is QIF?

The Quarterly Investment Forum (QIF) is an ongoing cross-investment team discussion and debate about the most relevant active risks in major markets and across asset classes and funds.

Each QIF is a mix of 'top down' and 'bottom up' perspectives, beginning with a 'top down' discussion of the major macroeconomic themes identified by the Asset Allocation Team. Each quarter, a rotating roster of portfolio managers present a 'bottom up' view of major active risks in their portfolios.

We have a unique depth and breadth of investment expertise across traditional and alternative asset classes in all regions globally. The QIF leverages that expertise through regular, structured communication between investment teams. The ultimate goal is to improve client outcomes.

Subscribe now

Perspectives matter. Tune in to our insights.

Singapore Retail Investors


This website is not intended for and should not be accessed by persons located or resident in any jurisdiction where (by reason of that person's nationality, domicile, residence or otherwise) the publication or availability of this website is prohibited or contrary to local law or regulation or would subject any UBS entity to any registration or licensing requirements in such jurisdictions. It is your responsibility to be aware of, to obtain all relevant regulatory approvals, licenses, verifications and/or registrations under, and to observe all applicable laws and regulations of any relevant jurisdiction in connection with your entrance to this website. Each investment product and service referred to on this website is intended to be made available only to residents in Singapore.

UBS reserves the right to change, modify, add or remove content on the website as well as these terms at any time for any reason without notice. Such changes shall be effective immediately upon posting. You acknowledge that by accessing our website after we have posted changes to these terms, you are agreeing to these terms as modified.

The materials on this Website are distributed by UBS Asset Management (Singapore) Ltd (company registration number: 199308367C), which is licensed by Monetary Authority of Singapore ("MAS") in Singapore pursuant to the Securities and Futures Act (Chapter 289 of Singapore). UBS Asset Management (Singapore) Ltd is part of the Asset Management business division of UBS Group AG. UBS Asset Management (Singapore) Ltd together with UBS Group AG and its group companies shall collectively be referred to as "UBS".

The information contained in this Website has been prepared and is intended for general circulation. The information does not constitute advice and does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The investment services or products referred to in this Website may not be suitable for all investors. UBS recommends that you independently evaluate particular investments and strategies and seek independent advice from a financial adviser regarding the suitability of such investment products, taking into account your specific investment objectives, financial situation and particular needs, before making a commitment to purchase any investment products. Investment involves risks. You should be aware that investments may increase or decrease in value and that past performance is not indicative of future performance.

The information contained in this Website is not an offer to buy or sell or the solicitation of an offer to buy or sell any investment product or to participate in any particular trading strategy. UBS, its officers and/or employees may have interests in any of the investment products referred to on this Website by acting in various roles. UBS, its officers and/or employees may receive fees, commissions or other benefits for acting in those capacities. In addition, UBS, its officers and/or employees may buy or sell investment products as principal or agent and may effect transactions which are not consistent with the information set out in this Website.

You fully understand and agree that, by making available this Website, UBS should not be construed as making: (a) any endorsement of any investment product referred to in this Website; (b) any representation that UBS has performed any due diligence on any investment product referred to in this Website; or (c) any representation that the information in this Website is complete, accurate, clear, fair and not misleading. The use or reliance on any such information contained in this Website is at your own risk and any losses which may be suffered as a result of you entering into any investment are for your account and UBS shall not be liable for any losses arising from or incurred by you in connection therewith. UBS is not responsible or liable for the accuracy and completeness of any such information or the performance or outcome of any investment made by you after receipt of such information, irrespective of whether such information was provided at your request.

Using, copying, redistributing or republishing any part of this Website without prior written permission from UBS is prohibited. Any statements made regarding investment performance objectives, risk and/or return targets shall not constitute a representation or warranty that such objectives or expectations will be achieved or risks are fully disclosed. The information and opinions contained in this Website is based upon information obtained from sources believed to be reliable and in good faith but no responsibility is accepted for any misrepresentation, errors or omissions. All such information and opinions are subject to change without notice. A number of comments in this Website are based on current expectations and are considered “forward-looking statements”. Actual future results may prove to be different from expectations and any unforeseen risk or event may arise in the future. The opinions expressed are a reflection of UBS’s judgment at the time this document is compiled and any obligation to update or alter forward-looking statements as a result of new information, future events, or otherwise is disclaimed.

UBS does not hold out any of its officers and/or employees as having any authority to advise you, and UBS does not purport to advise you on any investment product. Any investment will be made at your sole risk and UBS is not and shall not, in any manner, be liable or responsible for the consequences of any investment.

This Website and its contents are provided on an “as is” and “as available” basis. UBS does not warrant: (a) the accuracy, timeliness, adequacy commercial value or completeness of this Website or its contents, and expressly disclaims any liability for errors, delays or omissions in the contents, or for any action taken in reliance on the contents; (b) that your use of and/or access to this Website or its contents, will be uninterrupted, timely, secure or free from errors or that any identified defect will be corrected; (c) that this Website or any content will meet your requirements or are free from any virus or other malicious, destructive or corrupting code, agent, program or macros; (d) that any information, instructions or communications posted or transmitted by you through this Website is secure and cannot be accessed by unauthorised third parties; and (e) that use of the contents in this Website by you will not infringe the rights of any third parties. No warranty of any kind, implied, express or statutory, including but not limited to the warranties of non-infringement of third party rights, title, merchantability, satisfactory quality or fitness for a particular purpose and freedom from computer virus or other malicious, destructive or corrupting code, agent, program or macros, is given in conjunction with this Website.

You hereby agree to indemnify UBS and any of its officers, employees or agents against, and to keep UBS and any of its officers, employees or agents harmless from, any claims (actual and threatened), settlement sums, liability, loss, damages, costs (including solicitor and client costs and expenses (legal or otherwise)), charges, expenses, actions, proceedings, whether foreseeable or not which we may sustain, suffer or incur, directly or indirectly out of or in the course of or in connection with any the following: (a) any use of this Website or the contents by you, or any part thereof; (b) UBS having made available the Website; (c) any breach of these Terms by you, however arising; or (d) any negligence, act or omission, wilful default, unlawful act, fraud and/or misconduct on your part or violation of any rights of another person or entity by you.

The funds referred to in this Website have been authorised or recognised by the MAS for sale to the public in Singapore (the “Funds”). Copies of the registered Singapore prospectuses ("Prospectuses") referred to in this Website have been lodged with and registered by the MAS. The MAS assumes no responsibility for the contents of the Prospectuses. The registration of the Prospectuses by the MAS does not imply that the SFA or any other legal or regulatory requirements have been complied with.

MAS registration is not a recommendation or endorsement of a Fund nor does it guarantee the commercial merits or performance of such Fund. It does not mean that a Fund is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors. UBS Asset Management (Singapore) Ltd has been appointed as the representative for the Funds in Singapore for the purposes of performing administrative and other related functions relating to the offer of Shares under Section 287 of the Securities and Futures Act, Chapter 289 of Singapore (the "SFA") and such other functions as the MAS may prescribe.

You may not assign your rights under the Terms without our prior written consent. UBS Asset Management (Singapore) Ltd may assign our rights under the Terms to any third party.

No person or entity who is not a party to the Terms shall have any right under the Contracts (Rights of Third Parties) Act, Chapter 53B of Singapore or other similar laws to enforce any term of the Terms regardless of whether such person or entity has been identified by name, as a member of a class or as answering a particular description. For the avoidance of doubt, this shall not affect the rights of any permitted assignee or transferee of the Terms.

These Terms shall be governed by, and shall be construed in accordance with, the laws of Singapore. The courts of Singapore shall have exclusive jurisdiction to hear and determine any suit, action or proceeding, and to settle any disputes, which may arise out of or in connection with these Terms and, for such purposes, you agree to submit  to the jurisdiction of the courts of Singapore. Each party hereby waives any objection which it might at any time have to the courts of Singapore being nominated as the forum to hear and determine any proceedings and to settle any disputes and agrees not to claim that the courts of Singapore are not a convenient or appropriate forum.

© UBS 2021 - the key symbol and UBS are among the registered and unregistered trademarks of UBS. All rights reserved.


More insights

Asset Management services and solutions in your location

Please select your region

For further information on what we can offer you, please get in touch.